The crisis in soaring drug prices has produced not merely a new class of public enemies to skewer -- step forward, Martin Shkreli! -- but the best evidence yet that the nation's healthcare regulatory priorities are out of whack.
How badly the regulators have failed is the theme of an article by Jeremy Greene of the Johns Hopkins School of Medicine, just published in the Journal of the American Medical Assn. His argument is that the Food and Drug Administration has ample authority to quell profiteering in the generic drug market, but hasn't used it.
